DTX1

DTX1 is a cytoplasmic E3 ubiquitin ligase that regulates Notch signaling and inflammatory responses through ubiquitination of distinct substrates in a context-dependent manner. On tubulovesicular recycling endosomes, DTX1 ubiquitinates the lipid kinase PI5P4Kγ to control PI(4,5)P2-dependent Notch1 recycling via Rab4a-mediated transport; DTX1 silencing enhances Notch1 surface levels and signaling (PMID:29440432). Beyond Notch, DTX1 ubiquitinates NLRP3 for proteasomal degradation to suppress hepatocyte pyroptosis (PMID:39319341), and ubiquitinates TUBB3 in macrophages to block AKT-driven M2 polarization and restrain hepatocellular carcinoma progression (PMID:41577987). DTX1 also promotes microglial M1 polarization through the NF-κB/IRF5 pathway, contributing to neuroinflammation after traumatic brain injury (PMID:40660011).

1. 2000 Low

   Initial genomic characterization established DTX1 as a cytoplasmic Notch-pathway component encoded at 12q24, providing the foundation for functional studies but without direct biochemical evidence of its mechanism.

   Evidence Genomic characterization, cDNA analysis, and chromosomal mapping in human

   PMID:11153911

   Open questions at the time

   • No direct functional assay was performed; Notch-regulatory role inferred from Drosophila Deltex homology
   • No substrates or enzymatic activity demonstrated
   • Mapping within the Noonan syndrome critical region was never followed up with causal evidence
2. 2018 High

   The key mechanistic question — how does DTX1 regulate Notch receptor trafficking? — was answered by showing DTX1 ubiquitinates PI5P4Kγ on recycling endosomes, thereby modulating PI(4,5)P2-dependent Rab4a-mediated Notch1 recycling to the cell surface.

   Evidence siRNA silencing, activity-based ubiquitination substrate screen, immunolocalization, pharmacological PI5P4Kγ inhibition, lysine-less Notch1 mutant rescue in cultured cells

   PMID:29440432

   Open questions at the time

   • In vivo validation of the PI5P4Kγ-ubiquitination mechanism is lacking
   • Structural basis for DTX1 substrate recognition is unresolved
   • Whether DTX1 also directly ubiquitinates Notch1 itself remains debated
3. 2022 Low

   A study linked reduced Dtx1 expression (via miR-210-3p targeting) to impaired β-cell AKT/mTOR signaling and gestational diabetes, suggesting DTX1 sustains signaling in pancreatic cells, though the direct biochemical mechanism was not defined.

   Evidence miRNA overexpression, siRNA knockdown, western blotting, rescue experiments in mouse GDM model

   PMID:36374959

   Open questions at the time

   • DTX1 ubiquitin ligase activity was not directly assayed; pathway placement is correlative
   • No substrate for DTX1 was identified in β-cells
   • Single-lab study without independent replication
4. 2024 Medium

   DTX1 was shown to ubiquitinate NLRP3 for proteasomal degradation, establishing a Notch-independent anti-inflammatory function: DTX1 suppresses inflammasome-driven hepatocyte pyroptosis, with its own transcription activated by HNF4α.

   Evidence Reciprocal Co-IP, ubiquitination assay, ChIP for HNF4α on DTX1 promoter, luciferase reporter, siRNA/overexpression with pyroptosis readout in hepatocytes

   PMID:39319341

   Open questions at the time

   • Ubiquitin chain type on NLRP3 was not characterized
   • In vivo validation in liver injury models is needed
   • Whether HNF4α-DTX1 axis operates in non-hepatic inflammasome contexts is unknown
5. 2024 Medium

   Extrachromosomal circular DNA containing the DTX1 locus was shown to drive its transcription in transformed cells, revealing a non-canonical mechanism of DTX1 upregulation linked to cell survival and ferroptosis resistance.

   Evidence Circle-seq, RNA-seq, CRISPR/Cas9 decircularization, DNA-FISH, xenograft assay, ferroptosis inhibitor rescue

   PMID:39587541

   Open questions at the time

   • The downstream ubiquitin ligase substrates mediating ferroptosis resistance were not identified
   • Generalizability of eccDNA-driven DTX1 expression beyond hydroquinone-transformed cells is unclear
   • Mechanism by which DTX1 inhibits ferroptosis is entirely uncharacterized
6. 2025 Medium

   DTX1 was shown to promote microglial M1 polarization via NF-κB/IRF5 signaling after traumatic brain injury, establishing a pro-inflammatory role in the CNS that contrasts with its anti-inflammatory NLRP3-degradation function in hepatocytes.

   Evidence Adenoviral overexpression and siRNA knockdown in rat TBI model and cultured microglia with cytokine and marker readouts

   PMID:40660011

   Open questions at the time

   • The direct substrate(s) ubiquitinated by DTX1 to activate NF-κB/IRF5 in microglia remain unknown
   • Findings are from a single lab without independent confirmation
   • Relationship between Notch signaling and NF-κB/IRF5 activation in this context is unresolved
7. 2026 Medium

   DTX1 was found to ubiquitinate TUBB3 for degradation in Kupffer cells, disrupting AKT signaling via the PTEN-AKT axis and suppressing M2 macrophage polarization and hepatocellular carcinoma growth — expanding the substrate repertoire to cytoskeletal targets.

   Evidence Co-IP, ubiquitination assay, TUBB3 knockdown/overexpression, DTX1 overexpression, in vivo hepatocellular carcinoma tumor models

   PMID:41577987

   Open questions at the time

   • How DTX1 recognizes TUBB3 versus other tubulins is unexplained
   • Ubiquitin chain linkage type and specific lysine sites on TUBB3 are not mapped
   • Whether this anti-tumor mechanism operates in non-hepatic tumor microenvironments is unknown

• A unified model of how DTX1 selects among its diverse substrates (PI5P4Kγ, NLRP3, TUBB3) in different cell types, and whether these activities are coordinated or independent, remains unresolved.
• No structural data exist for DTX1 or any DTX1–substrate complex
• The ubiquitin chain types generated by DTX1 on different substrates have not been systematically characterized
• Cell-type-specific regulation of DTX1 substrate selection is unexplored